Rhumbline Advisers Intra Cellular Therapies, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q4 2024

A detailed history of Rhumbline Advisers transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 125,644 shares of ITCI stock, worth $16.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
125,644
Previous 126,158 0.41%
Holding current value
$16.1 Million
Previous $9.22 Million 13.76%
% of portfolio
0.01%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 30, 2025
SELL
$71.19 - $91.57 $36,591 - $47,066
-514 Reduced 0.41%
125,644 $10.5 Million
Q3 2024

Nov 12, 2024
BUY
$67.99 - $80.84 $65,406 - $77,768
962 Added 0.77%
126,158 $9.22 Million
Q2 2024

Aug 01, 2024
SELL
$64.76 - $79.84 $770,125 - $949,457
-11,892 Reduced 8.67%
125,196 $8.57 Million
Q1 2024

May 09, 2024
BUY
$64.37 - $75.65 $141,420 - $166,203
2,197 Added 1.63%
137,088 $9.49 Million
Q4 2023

Feb 08, 2024
SELL
$46.37 - $73.65 $109,943 - $174,624
-2,371 Reduced 1.73%
134,891 $9.66 Million
Q3 2023

Nov 09, 2023
BUY
$52.09 - $64.1 $146,320 - $180,056
2,809 Added 2.09%
137,262 $7.15 Million
Q2 2023

Aug 08, 2023
BUY
$54.67 - $66.44 $335,455 - $407,675
6,136 Added 4.78%
134,453 $8.51 Million
Q1 2023

May 11, 2023
BUY
$43.8 - $56.99 $16,205 - $21,086
370 Added 0.29%
128,317 $6.95 Million
Q4 2022

Feb 14, 2023
BUY
$44.07 - $54.45 $260,850 - $322,289
5,919 Added 4.85%
127,947 $6.77 Million
Q3 2022

Nov 10, 2022
BUY
$42.7 - $59.99 $415,983 - $584,422
9,742 Added 8.68%
122,028 $5.68 Million
Q2 2022

Aug 11, 2022
BUY
$43.0 - $65.64 $1.05 Million - $1.6 Million
24,404 Added 27.77%
112,286 $6.41 Million
Q1 2022

May 12, 2022
BUY
$38.74 - $62.09 $451,049 - $722,913
11,643 Added 15.27%
87,882 $5.38 Million
Q4 2021

Feb 10, 2022
SELL
$35.2 - $53.42 $33,686 - $51,122
-957 Reduced 1.24%
76,239 $3.99 Million
Q3 2021

Nov 12, 2021
BUY
$28.72 - $42.49 $95,637 - $141,491
3,330 Added 4.51%
77,196 $2.88 Million
Q2 2021

Aug 05, 2021
SELL
$29.3 - $44.5 $590,688 - $897,120
-20,160 Reduced 21.44%
73,866 $3.02 Million
Q1 2021

May 06, 2021
SELL
$30.8 - $39.51 $234,603 - $300,947
-7,617 Reduced 7.49%
94,026 $3.19 Million
Q4 2020

Feb 10, 2021
BUY
$23.34 - $32.22 $284,491 - $392,729
12,189 Added 13.63%
101,643 $3.23 Million
Q3 2020

Nov 12, 2020
SELL
$17.61 - $31.86 $199,045 - $360,113
-11,303 Reduced 11.22%
89,454 $2.3 Million
Q2 2020

Aug 13, 2020
BUY
$14.35 - $26.64 $265,130 - $492,200
18,476 Added 22.45%
100,757 $2.59 Million
Q1 2020

May 06, 2020
BUY
$12.31 - $33.12 $171,355 - $461,030
13,920 Added 20.36%
82,281 $1.27 Million
Q4 2019

Feb 05, 2020
BUY
$7.26 - $38.49 $7,383 - $39,144
1,017 Added 1.51%
68,361 $2.35 Million
Q3 2019

Oct 23, 2019
BUY
$7.47 - $14.03 $27,937 - $52,472
3,740 Added 5.88%
67,344 $503,000
Q2 2019

Aug 14, 2019
BUY
$10.65 - $14.29 $34,484 - $46,271
3,238 Added 5.36%
63,604 $826,000
Q1 2019

May 01, 2019
SELL
$10.9 - $14.09 $5,515 - $7,129
-506 Reduced 0.83%
60,366 $735,000
Q4 2018

Jan 31, 2019
BUY
$10.36 - $20.96 $191,463 - $387,361
18,481 Added 43.6%
60,872 $693,000
Q3 2018

Nov 07, 2018
SELL
$17.77 - $22.9 $163,572 - $210,794
-9,205 Reduced 17.84%
42,391 $920,000
Q2 2018

Aug 06, 2018
BUY
$17.33 - $23.4 $152,157 - $205,452
8,780 Added 20.51%
51,596 $912,000
Q1 2018

May 02, 2018
SELL
$15.16 - $25.49 $5,624 - $9,456
-371 Reduced 0.86%
42,816 $901,000
Q4 2017

Feb 09, 2018
SELL
$14.27 - $16.79 $6,978 - $8,210
-489 Reduced 1.12%
43,187 $625,000
Q3 2017

Nov 06, 2017
BUY
$10.77 - $22.1 $470,390 - $965,239
43,676
43,676 $689,000

Others Institutions Holding ITCI

# of Institutions
391
Shares Held
88.5M
Call Options Held
220K
Put Options Held
140K
View Full List

About Intra-Cellular Therapies, Inc.

ITCI Quotes by TradingView
  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $12.1B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email